Search - PracticalNeurology

Filter Search Results

Order:

Content Type:

Diseases:

Media Type:

Showing 701-710 of 2293 results for "".

Catherine Chu, MD, to Lead Pediatric Neurology at Kennedy Krieger and Johns Hopkins
https://practicalneurology.com/news/catherine-chu-md-to-lead-pediatric-neurology-at-kennedy-krieger-and-johns-hopkins/2475483/
Catherine Chu, MD, MA, MMSc, has been named Vice President of Child Neurology of the Kennedy Krieger Institute and will also serve as Director of the Division of Pediatric Neurology and the John M. Freeman Pediatric Epilepsy Center at Johns Hopkins Children’s Center. According to a statement rele
In Memoriam: Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANA
https://practicalneurology.com/news/in-memoriam-martin-a-samuels-md-dsc-hon-faan-macp-frcp-fana/2470226/
Martin A. Samuels, MD, DSc (hon), FAAN, MACP, FRCP, FANA, the first named Miriam Sydney Joseph Distinguished Professor of Neurology at Harvard Medical School, passed away on June 6, 2023, at age 77.
Earlier Ocrelizumab Treatment Reduces Disability Progression, Potentially Has Shorter Infusion Times and Safety in Pregnancy
https://practicalneurology.com/news/earlier-ocrelizumab-treatment-reduces-disability-progression-potentially-has-shorter-infusion-times-and-safety-in-pregnancy/2469021/
In the open-label extension of OPERA I and II trials (NCT01247324 and NCT01412333) fewer participants with relapsing MS who were treated with ocrelizumab (Ocrevus; Genentech
AAN Issues Guideline on Vaccines for People With Multiple Sclerosis
https://practicalneurology.com/news/aan-issues-guideline-on-vaccines-for-people-with-multiple-sclerosis/2469002/
In a guideline published in the current online issue of Neurology, the American Academy of Neurology (AAN) recommends that people with multiple sclerosis (MS) receive recommended vaccinations, including y
New Consensus Statements on Smoldering Disease in Multiple Sclerosis Developed
https://practicalneurology.com/news/new-consensus-statements-on-smoldering-disease-in-multiple-sclerosis-developed/2470312/
An international panel has developed consensus-driven statements on smoldering disease (SD) in multiple sclerosis (MS), including domains such as definition, onset, pathology, clinical and imaging manifestations, and detection modalities. The goal of the panel is to educate the neurology communit
International Advisory Committee on Clinical Trials in Multiple Sclerosis Suggests New Framework for Defining Progression of Multiple Sclerosis
https://practicalneurology.com/news/international-advisory-committee-on-clinical-trials-in-multiple-sclerosis-suggests-new-framework-for-defining-progression-of-multiple-sclerosis/2470199/
The International Advisory Committee on Clinical Trials in Multiple Sclerosis proposed a new mechanism-driven framework for defining progression in multiple sclerosis (MS). The recommendations presented at the 2023 Annual M
Neurotrophic Factor-Secreting Stem Cell Treatment Improves Function in Progressive Multiple Sclerosis
https://practicalneurology.com/news/neurotrophic-factor-secreting-stem-cell-treatment-improves-function-in-progressive-multiple-sclerosis/2470024/
As published in Multiple Sclerosis, off-the-shelf growth factor-secreting stem cell (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY) treatment of people with progressive multiple sclerosis (MS) im
Multiple Sclerosis Prevalence Updates
https://practicalneurology.com/news/multiple-sclerosis-prevalence-updates/2469900/
Based on research published in Neurology, the prevalence of multiple sclerosis (MS) is similar in Black people and white people, whereas prevalence is lower in people from the Asian and Hispanic communiti
Risk-Benefit Profile of Ozanimod for Multiple Sclerosis Did Not Change With COVID-19
https://practicalneurology.com/news/risk-benefit-profile-of-ozanimod-for-multiple-sclerosis-did-not-change-with-covid-19/2469834/
In the open-label extension DAYBREAK study (NCT02576717) among participants in 4 clinical trials of ozanimod (Zeposia; Bristol Myers Squibb, New York, NY) for multiple sclerosis (MS), the effect of COVID-19 was evaluated. The 2,494 par
Autologous Mesenchymal Stem Cells Expressing Neurotrophic Factors Improved Function and Biomarkers in Progressive Multiple Sclerosis
https://practicalneurology.com/news/autologous-mesenchymal-stem-cells-expressing-neurotrophic-factors-improved-function-and-biomarkers-in-progressive-multiple-sclerosis/2469728/
In a trial (NCT03799718) of autologous neurotrophic mesenchymal stem cells (MSC-NTF) (NurOwn; BrainStorm Cell Therapeutics, New York, NY), 18 individuals with progressive MS were treated, and 16 c

71/11